The best part of the Inderes forum is when Eka comes to challenge your investment thesis in the thread of a company you own, thanks!
I can’t say why others own it, but I can tell you why I do. It’s impossible to summarize this in a single post, but let’s start with the basics:
The starting point of the investment thesis is that there are just over 20 million small and medium-sized enterprises (SMEs) in Europe. A significant portion of these companies are privately owned by entrepreneurs and families, meaning they aren’t part of any mega-corporation yet. A large number of these companies were founded by older generations, so many will face retirement in the coming years and decades. For almost all of these companies, a successor cannot be found among heirs or family, for numerous different reasons. Because of this, approx. 15,000 SMEs are sold in Europe annually.
Röko is a “forever owner” of such SMEs. It buys them and, in principle, owns them forever and reinvests the money to buy more. This creates that compounding machine in Excel. The company basically has endless opportunities to reinvest cash flows in the coming decades. It’s obviously easy to grow through acquisitions, and anyone can buy whatever companies to grow if they have endless money.
This brings us to ROIC. I think this part is extremely simple; you don’t even need Excel, mental math is enough
Röko’s business is ultimately capital allocation, effectively stock picking in private firms. If you pay fair value (required return is high because it’s private and small) for a good SME that is:
- Historically very profitable
- Reasonably defensive
- Possesses pricing power
- Needs very little maintenance investment (capex)
…then such companies constantly produce good cash flow that can be reinvested. These companies wouldn’t be remarkable investments on their own, but with masterful reinvestment of cash flows, magic starts to happen if you can do it for decades. In many investment cases, the problem is exactly that reinvesting cash flows is impossible to predict, or the company simply has nothing to invest in with a good return. In serial acquirers and investment companies, this reinvestment problem is inherently solved.
Röko targets approx. 15% growth, the prerequisites of which have been calculated several times in the thread. My thesis is that Röko can maintain this pace for a truly long time—a decade or two.
Röko’s acquisition criteria:
Maybe it can be summarized as: if successful, Röko will become a kind of mini-Berkshire, but with European SMEs and without the insurance float
So, it’s pretty useless to expect +20% turbocharged annual returns, but purely by reinvesting cash flows, there are reasonable chances for, say, 15% annual returns on paper.
That’s still a multi-bagger over decades. So this is an investment that requires time and patience 
A topic for a completely different post is what all this described above requires from both the capital-allocating headquarters and the cash-flow-generating subsidiaries. In practice, Röko is a lean 8-person headquarters and a group of dozens of entrepreneurs with their employees in very diverse industries. Running such an entity efficiently and with the right incentives is no easy feat.
Also fishing in the same waters are a whole bunch of other serial acquirers, PE clowns (private equity), and industrial/strategic buyers. Röko’s angle here is the forever ownership and decentralized operating model, where acquired companies are run entrepreneurially even after the transaction, with minority ownership keeping incentives in check
Overall, very similar logic for value creation as Berkshire’s unlisted investments, just without the insurance companies. This, of course, requires masters at allocating capital, which I believe Röko has.
I’ll add that in an investment case like this, there are no rocket-ship drivers; instead, this is damn boring basic work, entrepreneurship, and capital allocation
Things happen slowly, one acquisition at a time, and you have to look at the case with a very long-term view. This is like watching a tree grow in the yard. Nothing really happens in a year, but in a decade or two, a lot. There are no exciting pharmaceutical companies here waiting for a breakthrough to ten-bag in a moment 